

Press Release

BioCision's ThawSTAR Automated Cell Thawing Platform Joins TrakCel Partner Program

Leading-edge companies team up to accelerate cell therapy supply chain excellence

CARDIFF, WALES, UK May XX, 2016 – TrakCel Ltd., a pioneer in cell therapy process management and supply chain integration technology today announces BioCision, LLC as a new member of the TrakCel's Connected Services program.

The Connected Services program seamlessly integrates technology from world-leading organizations that are essential to the cell therapy supply chain, into the TrakCel ecosystem to provide real time visibility and actionable insights. Partnering companies benefit by integrating their core capabilities in the cell therapy supply chain and extending their business reach into the industry.

BioCision, LLC, leader in thermal management technologies from R&D to point-of-care, has worked to address the common challenges associated with conventional unstandardized methods of thawing. BioCision's award-winning intuitive ThawSTAR® cell thawing platform utilizes adaptive sensing technology that incorporates algorithms to deliver a consistent and reproducible thaw profile and endpoint to each vial. This standardizes the thawing process by eliminating variability and provides a significant reduction in cell handling risk in a clinical setting.

"TrakCel partners with industry leaders to integrate novel technologies needed for the successful commercialization of cellular therapeutics." said Samuel Kent, Senior Vice President of Global Sales and Business Development, BioCision, LLC. "By integrating the ThawSTAR platform into the Connected Service program, we are able to offer a real-time window into a crucial stage of the cell therapy handling process. By including tracking information such as temperature recording and vial identification, we enable critical de-risking checks like patient-therapy matching in early pre-clinical development through to point-of care."

TrakCel's technology integrates and automates the entire cell therapy process while providing real-time audit logs and chain-of-custody records to stakeholders. The Connected Services program accelerates cell therapy success by enhancing TrakCel's cell therapy supply chain management platform with links to participant firms that specialize in logistics, cell therapy manufacturing, patient treatment, storage, compliance and other essential tasks in the supply chain.

"The importance of automation and standardization of the thawing process for cell therapies remain under-appreciated for frozen cell therapeutics" said Jon Curley, CTO and Partner Program Spokesman, TrakCel Ltd. "BioCision's technology brings reproducibility and reliability into that process and this partnership better positions our cell therapy customers to achieve excellence in cold chain management".

For more information on the TrakCel 'Connected Services' program click on the following link: <http://trakcel.com/partner-ecosystem.html>

For more information about BioCision's automated ThawSTAR platform click on the following link: <http://www.biocision.com/products/thawstar-automated-cell-thawing/>

About TrakCel

TrakCel's cell therapy process management solution improves clinical study efficacy and accelerates product scale-up/scale-out by implementing communications technology to integrate the supply chain from end-to-end. The technology provides interactive instructions to professionals within the cell therapy supply chain and gives stakeholders on-demand visibility of procedural results and chain-of-custody data for immediate traceability, validation and compliance audits. Founded in 2012, TrakCel technology has been adopted by GlaxoSmithKline and other leaders in the cell therapy industry. TrakCel is based in Cardiff, Wales, UK.

TrakCel Ltd.

www.trakcel.com

About BioCision, LLC

BioCision is a life science research and development company that provides tools to standardize critical processes throughout the healthcare industry. BioCision's award-winning portfolio of translational products can be integrated throughout research, development and manufacturing workflows, enabling consistent temperature control for sensitive therapeutics and biological samples. By addressing temperature stability, BioCision strives to improve the success of therapeutic discovery and development, and enable effective care delivery.

For more information visit www.biocision.com, or visit the BioCision blog for news and expert insight at <http://blog.biocision.com/>.

Media contact information:

TrakCel:

TrakCel: PR Team publicrelations@trakcel.com

+44 (0)2920 483729

BioCision:

Marla Kertzman

mkertzman@biocision.com

209 852 9027